JP2015533163A - 多発性硬化症における視床損傷を低減するためのラキニモド - Google Patents

多発性硬化症における視床損傷を低減するためのラキニモド Download PDF

Info

Publication number
JP2015533163A
JP2015533163A JP2015536853A JP2015536853A JP2015533163A JP 2015533163 A JP2015533163 A JP 2015533163A JP 2015536853 A JP2015536853 A JP 2015536853A JP 2015536853 A JP2015536853 A JP 2015536853A JP 2015533163 A JP2015533163 A JP 2015533163A
Authority
JP
Japan
Prior art keywords
laquinimod
subject
thalamic
administered
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015536853A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015533163A5 (enExample
Inventor
フィリッピ、マッシモ
コミ、ジアンカルロ
ロッカ、マリア、アシュンタ
Original Assignee
テバ ファーマシューティカル インダストリーズ リミティド
テバ ファーマシューティカル インダストリーズ リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by テバ ファーマシューティカル インダストリーズ リミティド, テバ ファーマシューティカル インダストリーズ リミティド filed Critical テバ ファーマシューティカル インダストリーズ リミティド
Publication of JP2015533163A publication Critical patent/JP2015533163A/ja
Publication of JP2015533163A5 publication Critical patent/JP2015533163A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dispersion Chemistry (AREA)
JP2015536853A 2012-10-12 2013-10-09 多発性硬化症における視床損傷を低減するためのラキニモド Pending JP2015533163A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261713256P 2012-10-12 2012-10-12
US61/713,256 2012-10-12
PCT/US2013/064061 WO2014058979A2 (en) 2012-10-12 2013-10-09 Laquinimod for reducing thalamic damage in multiple sclerosis

Publications (2)

Publication Number Publication Date
JP2015533163A true JP2015533163A (ja) 2015-11-19
JP2015533163A5 JP2015533163A5 (enExample) 2016-11-24

Family

ID=50475887

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015536853A Pending JP2015533163A (ja) 2012-10-12 2013-10-09 多発性硬化症における視床損傷を低減するためのラキニモド

Country Status (18)

Country Link
US (2) US20140107154A1 (enExample)
EP (1) EP2961406A4 (enExample)
JP (1) JP2015533163A (enExample)
KR (1) KR20150080509A (enExample)
CN (1) CN105263325A (enExample)
AR (1) AR092993A1 (enExample)
AU (2) AU2013329348A1 (enExample)
BR (1) BR112015007782A2 (enExample)
CA (1) CA2884272A1 (enExample)
CL (2) CL2015000732A1 (enExample)
EA (1) EA201590726A1 (enExample)
HK (1) HK1218865A1 (enExample)
IL (1) IL237745A0 (enExample)
MX (1) MX2015004564A (enExample)
PE (1) PE20151435A1 (enExample)
SG (1) SG11201501874TA (enExample)
TW (1) TW201420101A (enExample)
WO (1) WO2014058979A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015505564A (ja) 2012-02-03 2015-02-23 テバ ファーマシューティカル インダストリーズ リミティド 第一選択の抗ＴＮＥα療法に失敗したクローン病患者を治療するためのラキニモドの使用
JP6215238B2 (ja) 2012-02-16 2017-10-18 テバ ファーマシューティカル インダストリーズ リミティド Ｎ−エチル−ｎ−フェニル−１，２−ジヒドロ−４，５−ジ−ヒドロキシ−１−メチル−２−オキソ−３−キノリンカルボキサミド、その製剤、および使用
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
MX2015010296A (es) * 2013-02-15 2016-05-05 Teva Pharma Tratamiento de formas progresivas de esclerosis multiple con laquinimod.
EP3082814A4 (en) * 2013-12-20 2017-06-21 Teva Pharmaceutical Industries Ltd. Use of laquinimod to delay huntington's disease progression
AU2015253330A1 (en) 2014-04-29 2016-12-01 Teva Pharmaceutical Industries Ltd. Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status
MX386778B (es) 2015-03-09 2025-03-19 Intekrin Therapeutics Inc Métodos para el tratamiento de enfermedad de hígado graso no alcohólico y/o lipodistrofia.
WO2017048457A1 (en) * 2015-09-18 2017-03-23 Teva Pharmaceuticals Industries Ltd. Combination of laquinimod and pridopidine to treat multiple sclerosis
EP3512512A4 (en) * 2016-09-13 2020-06-03 Intekrin Therapeutics, Inc. TREATMENT OF MULTIPLE SCLEROSIS WITH CHS-131
CA3058806A1 (en) 2017-04-03 2018-10-11 Coherus Biosciences Inc. Ppar.gamma. agonist for treatment of progressive supranuclear palsy
CN113397757A (zh) * 2021-06-07 2021-09-17 温州医科大学 用于测试拉喹莫德在治疗缺血性脑卒中的作用的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1850840A2 (en) * 2005-01-13 2007-11-07 Sirtris Pharmaceuticals, Inc. Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders
MX2009000645A (es) * 2006-07-17 2009-03-06 Novartis Ag Derivados de sulfonilaminocarbonilo de amidas de acido biliar para utilizarse en la forma de inmunomoduladores.
TW201014605A (en) * 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
DK2442651T3 (en) * 2009-06-19 2015-09-21 Teva Pharma Treatment of multiple sclerosis with laquinimod
PT2467372T (pt) * 2009-08-10 2016-08-23 Teva Pharma Tratamento de distúrbios relacionados com bdnf usando laquinimod
US20130035390A1 (en) * 2010-01-13 2013-02-07 Ramot At Tel-Aviv University Ltd. Treatment of multiple sclerosis
SG10201509831XA (en) * 2010-12-07 2015-12-30 Teva Pharma Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients
ES2602794T3 (es) * 2011-03-31 2017-02-22 Pfizer Inc Piridinonas bicíclicas novedosas
EP2766020A4 (en) * 2011-10-12 2015-04-01 Teva Pharma TREATMENT OF MULTIPLE SCLEROSIS BY COMBINING LAQUINIMOD AND FINGOLIMOD
AR090885A1 (es) * 2012-05-02 2014-12-10 Teva Pharma Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ARCH NEUROL, vol. 61(2), JPN6017024652, 2004, pages 226 - 230, ISSN: 0003931146 *
N ENGL J MED, vol. 366(11), JPN6017024651, 15 March 2012 (2012-03-15), pages 1000 - 1009, ISSN: 0003931145 *

Also Published As

Publication number Publication date
HK1218865A1 (zh) 2017-03-17
CA2884272A1 (en) 2014-04-17
WO2014058979A3 (en) 2015-08-20
US20140107154A1 (en) 2014-04-17
IL237745A0 (en) 2015-05-31
EP2961406A2 (en) 2016-01-06
KR20150080509A (ko) 2015-07-09
CN105263325A (zh) 2016-01-20
PE20151435A1 (es) 2015-10-15
CL2015000732A1 (es) 2015-08-07
SG11201501874TA (en) 2015-05-28
WO2014058979A8 (en) 2015-04-16
MX2015004564A (es) 2015-07-21
BR112015007782A2 (pt) 2017-07-04
EA201590726A1 (ru) 2015-10-30
CN105263325A8 (zh) 2017-07-14
WO2014058979A2 (en) 2014-04-17
AR092993A1 (es) 2015-05-13
US20160296511A1 (en) 2016-10-13
TW201420101A (zh) 2014-06-01
CL2016002873A1 (es) 2017-04-17
AU2017203896A1 (en) 2017-06-29
AU2013329348A1 (en) 2015-05-28
EP2961406A4 (en) 2017-01-04

Similar Documents

Publication Publication Date Title
JP2015533163A (ja) 多発性硬化症における視床損傷を低減するためのラキニモド
CN103260624B (zh) 拉喹莫德用于在多发性硬化症患者中减少疲劳、改善功能状态和改善生活品质的用途
JP2017222691A (ja) 多発性硬化症を治療するための高投与量ラキニモドの使用
ES2548999T3 (es) Tratamiento de la esclerosis múltiple con laquinimod
JP2017061482A (ja) ラキニモドおよびインターフェロンβを組み合わせた多発性硬化症の治療
JP2016510343A (ja) ラキニモドを用いる多発性硬化症の治療
JP2017514824A (ja) 能力障害度が高い再発寛解型多発性硬化症（ｒｒｍｓ）患者の処置のためのラキニモド
TW201408300A (zh) 以拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）及氨吡啶（ｆａｍｐｒｉｄｉｎｅ）之組合治療多發性硬化症
HK1224555A1 (en) Use of high dose laquinimod for treating multiple sclerosis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161006

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161006

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170704

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170926

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20181204